Clinical trial
Prolonged Daily Temozolomide for Low-Grade Glioma
NCT00165360 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165360 |
|---|---|
| Title | Prolonged Daily Temozolomide for Low-Grade Glioma |
| Official title | A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Schering-Plough Industry Brigham and Women's Hospital University of Virginia |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Astrocytoma, Oligodendroglioma |
| Intervention type | Drug |
| Interventions | Temozolomide |
| Enrollment | 46 |
| Start date | Sep 1, 2001 |
| Primary completion | Dec 1, 2006 |
| Completion | Sep 1, 2009 |
| First posted | Sep 14, 2005 |
| Last update posted | Nov 2, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: